CODX Historical Income Statement

CODX Stock

USD 0.94 0.01 1.08%

Historical analysis of Co Diagnostics income statement accounts such as Selling General Administrative of 15 M, Total Revenue of 6.5 M or Gross Profit of 2.5 M can show how well Co Diagnostics performed in making a profits. Evaluating Co Diagnostics income statement over time to spot trends is a great complementary tool to traditional technical analysis and can indicate the direction of Co Diagnostics's future profits or losses.

Cash Flow Balance Sheet Income Statement

Yuan Drop

Covid

Financial Statement Analysis is much more than just reviewing and examining Co Diagnostics latest accounting reports to predict its past. Macroaxis encourages investors to analyze financial statements over time for various trends across multiple indicators and accounts to determine whether Co Diagnostics is a good buy for the upcoming year.

Net Income Gross Profit

Check out Trending Equities to better understand how to build diversified portfolios, which includes a position in Co Diagnostics. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in unemployment.

For more information on how to buy CODX Stock please use our How to Invest in Co Diagnostics guide.

About CODX Income Statement Analysis

Co Diagnostics Income Statement consists of revenues and expenses along with the resulting net income or loss. It represents the profit for the accounting period attributable to Co Diagnostics shareholders. The income statement also shows CODX investors and management if the firm made money during the period reported. The result of an income statement is the net income that is calculated after subtracting the expenses from revenue. It is essential to investors both as an absolute measure as well as earnings per share (i.e., EPS).

Co Diagnostics Income Statement Chart

At this time, Co Diagnostics' Non Operating Income Net Other is fairly stable compared to the past year.

Selling General Administrative Research Development Total Operating Expenses Selling And Marketing Expenses

Total Operating Expenses

The total costs associated with the day-to-day operations of a business, excluding the cost of goods sold but including selling, general, and administrative expenses.

Most accounts from Co Diagnostics' income statement are interrelated and interconnected. However, analyzing income statement accounts one by one will only give a small insight into Co Diagnostics current financial condition. On the other hand, looking into the entire matrix of income statement accounts, and analyzing their relationships over time can provide a more complete picture of the company financial strength now and in the future. Check out Trending Equities to better understand how to build diversified portfolios, which includes a position in Co Diagnostics. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in unemployment.

For more information on how to buy CODX Stock please use our How to Invest in Co Diagnostics guide.At this time, Co Diagnostics' Non Operating Income Net Other is fairly stable compared to the past year.

Co Diagnostics income statement Correlations

	Interest Expense	Selling General Administrative	Total Revenue	Gross Profit	Operating Income	Net Income From Continuing Ops	Ebit	Research Development	Total Operating Expenses	Income Before Tax	Total Other Income Expense Net	Net Income	Interest Income	Depreciation And Amortization	Selling And Marketing Expenses	Other Operating Expenses	Ebitda	Net Interest Income	Reconciled Depreciation	Non Operating Income Net Other	Non Recurring
Interest Expense		0.84	0.01	-0.02	-0.67	-0.7	-0.67	0.91	0.84	-0.67	0.9	-0.66	0.98	0.98	0.46	0.77	-0.65	0.97	0.99	1.0	-0.79
Selling General Administrative	0.84		0.52	0.49	-0.21	-0.27	-0.21	0.95	0.99	-0.21	0.78	-0.21	0.79	0.89	0.82	0.98	-0.19	0.92	0.9	0.84	-0.63
Total Revenue	0.01	0.52		1.0	0.72	0.68	0.72	0.34	0.51	0.72	0.12	0.72	-0.03	0.17	0.83	0.64	0.74	0.18	0.16	0.03	0.1
Gross Profit	-0.02	0.49	1.0		0.74	0.69	0.74	0.32	0.49	0.74	0.09	0.73	-0.07	0.14	0.83	0.61	0.76	0.14	0.13	-0.01	0.14
Operating Income	-0.67	-0.21	0.72	0.74		1.0	1.0	-0.4	-0.23	0.99	-0.49	0.99	-0.7	-0.54	0.26	-0.08	1.0	-0.54	-0.55	-0.65	0.65
Net Income From Continuing Ops	-0.7	-0.27	0.68	0.69	1.0		1.0	-0.46	-0.29	0.99	-0.51	1.0	-0.72	-0.58	0.19	-0.13	0.99	-0.57	-0.59	-0.68	0.66
Ebit	-0.67	-0.21	0.72	0.74	1.0	1.0		-0.4	-0.23	0.99	-0.49	0.99	-0.7	-0.54	0.26	-0.08	1.0	-0.54	-0.55	-0.66	0.65
Research Development	0.91	0.95	0.34	0.32	-0.4	-0.46	-0.4		0.98	-0.39	0.79	-0.4	0.89	0.94	0.75	0.93	-0.38	0.95	0.95	0.9	-0.76
Total Operating Expenses	0.84	0.99	0.51	0.49	-0.23	-0.29	-0.23	0.98		-0.21	0.76	-0.23	0.8	0.9	0.85	0.98	-0.2	0.91	0.9	0.83	-0.66
Income Before Tax	-0.67	-0.21	0.72	0.74	0.99	0.99	0.99	-0.39	-0.21		-0.51	1.0	-0.68	-0.54	0.27	-0.06	0.99	-0.52	-0.56	-0.65	0.59
Total Other Income Expense Net	0.9	0.78	0.12	0.09	-0.49	-0.51	-0.49	0.79	0.76	-0.51		-0.48	0.85	0.93	0.46	0.71	-0.47	0.87	0.93	0.91	-0.53
Net Income	-0.66	-0.21	0.72	0.73	0.99	1.0	0.99	-0.4	-0.23	1.0	-0.48		-0.67	-0.53	0.24	-0.07	0.99	-0.51	-0.55	-0.63	0.6
Interest Income	0.98	0.79	-0.03	-0.07	-0.7	-0.72	-0.7	0.89	0.8	-0.68	0.85	-0.67		0.94	0.4	0.73	-0.68	0.96	0.95	0.98	-0.85
Depreciation And Amortization	0.98	0.89	0.17	0.14	-0.54	-0.58	-0.54	0.94	0.9	-0.54	0.93	-0.53	0.94		0.58	0.84	-0.51	0.96	1.0	0.98	-0.72
Selling And Marketing Expenses	0.46	0.82	0.83	0.83	0.26	0.19	0.26	0.75	0.85	0.27	0.46	0.24	0.4	0.58		0.89	0.29	0.57	0.58	0.44	-0.24
Other Operating Expenses	0.77	0.98	0.64	0.61	-0.08	-0.13	-0.08	0.93	0.98	-0.06	0.71	-0.07	0.73	0.84	0.89		-0.05	0.86	0.84	0.77	-0.6
Ebitda	-0.65	-0.19	0.74	0.76	1.0	0.99	1.0	-0.38	-0.2	0.99	-0.47	0.99	-0.68	-0.51	0.29	-0.05		-0.52	-0.53	-0.63	0.63
Net Interest Income	0.97	0.92	0.18	0.14	-0.54	-0.57	-0.54	0.95	0.91	-0.52	0.87	-0.51	0.96	0.96	0.57	0.86	-0.52		0.97	0.97	-0.81
Reconciled Depreciation	0.99	0.9	0.16	0.13	-0.55	-0.59	-0.55	0.95	0.9	-0.56	0.93	-0.55	0.95	1.0	0.58	0.84	-0.53	0.97		0.98	-0.73
Non Operating Income Net Other	1.0	0.84	0.03	-0.01	-0.65	-0.68	-0.66	0.9	0.83	-0.65	0.91	-0.63	0.98	0.98	0.44	0.77	-0.63	0.97	0.98		-0.79
Non Recurring	-0.79	-0.63	0.1	0.14	0.65	0.66	0.65	-0.76	-0.66	0.59	-0.53	0.6	-0.85	-0.72	-0.24	-0.6	0.63	-0.81	-0.73	-0.79

Click cells to compare fundamentals

Co Diagnostics Account Relationship Matchups

Co Diagnostics income statement Accounts

	2019	2020	2021	2022	2023	2024 (projected)
Interest Expense	106.4K	175.0	473.5K	14.9M	17.1M	18.0M
Selling General Administrative	3.5M	8.3M	11.6M	14.3M	14.3M	15.0M
Total Revenue	215.0K	74.6M	97.9M	34.2M	6.8M	6.5M
Gross Profit	102.5K	58.0M	86.3M	28.7M	2.6M	2.5M
Operating Income	(5.9M)	41.7M	46.1M	(11.6M)	(42.7M)	(40.6M)
Net Income From Continuing Ops	(6.2M)	42.5M	36.7M	(14.2M)	(42.6M)	(40.4M)
Ebit	(5.9M)	41.7M	46.1M	(11.6M)	(42.7M)	(40.6M)
Research Development	1.4M	3.2M	15.0M	17.4M	23.0M	24.1M
Cost Of Revenue	112.4K	16.6M	11.6M	5.5M	4.2M	4.2M
Total Operating Expenses	6.0M	16.3M	40.2M	40.3M	44.1M	46.3M
Income Before Tax	(6.2M)	42.6M	45.6M	(18.8M)	(38.1M)	(36.2M)
Total Other Income Expense Net	(301.8K)	875.4K	(429.2K)	8.1M	4.6M	4.8M
Net Income Applicable To Common Shares	(6.2M)	42.5M	36.7M	(14.2M)	(16.4M)	(15.6M)
Net Income	(6.1M)	42.5M	36.7M	(14.2M)	(35.3M)	(33.6M)
Income Tax Expense	(126.4K)	90.5K	9.0M	(4.6M)	(2.8M)	(2.6M)
Interest Income	36.7K	97.2K	45.6K	704.0K	1.0M	1.1M
Depreciation And Amortization	(130.3K)	138.6K	335.4K	1.3M	1.2M	1.3M
Selling And Marketing Expenses	1.1M	4.7M	13.4M	7.3M	6.9M	4.3M
Other Operating Expenses	6.1M	32.9M	51.8M	45.8M	49.5M	52.0M
Ebitda	(6.0M)	41.8M	46.4M	(10.3M)	(41.5M)	(39.4M)
Net Interest Income	(69.8K)	97.2K	45.6K	704.0K	1.0M	1.1M
Reconciled Depreciation	65.9K	138.6K	335.4K	1.3M	1.2M	1.3M
Non Operating Income Net Other	(301.8K)	875.4K	(429.2K)	8.1M	9.4M	9.8M

Also Currently Popular

Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.

ESRT	Empire State Realty
C	Citigroup
C	Citigroup

Additional Tools for CODX Stock Analysis

When running Co Diagnostics' price analysis, check to measure Co Diagnostics' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Co Diagnostics is operating at the current time. Most of Co Diagnostics' value examination focuses on studying past and present price action to predict the probability of Co Diagnostics' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Co Diagnostics' price. Additionally, you may evaluate how the addition of Co Diagnostics to your portfolios can decrease your overall portfolio volatility.

Macroaxis helps investors of all levels and skills to maximize the upside of all their holdings and minimize the risk associated with market volatility, economic swings, and company-specific events. View terms and conditions

Feedback Blog

Made with optimal in San Francisco

2024 Macroaxis LLC

CODX Historical Income Statement

About CODX Income Statement Analysis

Co Diagnostics Income Statement Chart

Total Operating Expenses

Co Diagnostics income statement Correlations

Co Diagnostics Account Relationship Matchups

High Positive Relationship

High Negative Relationship

Co Diagnostics income statement Accounts

Also Currently Popular

Additional Tools for CODX Stock Analysis

COMMON DESTINATIONS

MAIN CATEGORIES

COMPANY

Non Operating Income Net Other	+ 1.0	Interest Expense
Gross Profit	+ 1.0	Total Revenue
Net Income From Continuing Ops	+ 1.0	Operating Income
Ebit	+ 1.0	Operating Income
Ebitda	+ 1.0	Operating Income
Ebit	+ 1.0	Net Income From Continuing Ops

Non Recurring	- 0.85	Interest Income
Non Recurring	- 0.81	Net Interest Income
Non Recurring	- 0.79	Non Operating Income Net Other
Non Recurring	- 0.79	Interest Expense
Non Recurring	- 0.76	Research Development
Non Recurring	- 0.73	Reconciled Depreciation